Latest News
Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story.
For media and press enquiries, please contact Louise Rowe at contact@resolution-tx.com
Nottingham is investigating a first-in-class cell treatment to help patients End Stage Liver Disease
Decompensated cirrhosis has a poor prognosis and few treatment options, with liver transplantation available to only a small minority of patients. Resolution Therapeutics is investigating RTX001, an engineered Regenerative Macrophage Therapy, as a potential alternative to improve survival and quality of life.
EMERALD Clinical Study: Q&A with Dr Paul Richardson & Dr Edward Britton, Royal Liverpool University Hospital
Dr Paul Richardson and Dr Edward Britton describes the End-Stage Liver Disease patient population being treated in the EMERALD clinical study which is evaluating Regenerative Macrophage Therapy as a potential new treatment.
The EMERALD clinical study: an overview with Prof. Ewan Forrest, Glasgow Royal Infirmary
EMERALD is an early-stage clinical trial of an innovative cell therapy for patients with end-stage liver disease, taking place in the UK and Spain. The therapy being tested, called Regenerative Macrophage Therapy, is designed to help even badly damaged livers recover, thus preventing disease from progressing further.
EMERALD Clinical Study: Q&A with Dr Kushala Abeysekera, Bristol Royal Infirmary Hospital
Liver disease kills over 12,000 people in the UK and 52,000 in the US every year. Once advanced, half of patients die within a year — and only 3% receive a transplant. Dr Kush Abeysekera explains why the status quo isn't working, and why Resolution Therapeutics is developing RTX001 as a potential alternative. First in a series on regenerative medicine in liver disease.